On December 11, 2025, Enliven Therapeutics, Inc. (ELVN) announced leadership changes and clinical development plans. The 8-K filing disclosed the appointment of Rick Fair as Chief Executive Officer with a base salary of $660,000 per year and the company's intention to initiate a pivotal Phase 3 trial for its chronic myeloid leukemia drug candidate ELVN-001 in 2026.

Rick Fair's compensation package includes an annual target bonus of 55 percent of his base salary, equating to $363,000, according to the employment agreement filed as Exhibit 10.1. The filing also grants Fair an option to purchase 875,000 shares of Enliven Therapeutics' Common Stock under the company's 2025 Inducement Equity Incentive Plan.

Sam Kintz, previously serving in a broader leadership capacity, has assumed the new role of Head of Pipeline, according to the filing. The company stated this change allows Kintz to focus on leading early-stage research programs while Fair oversees late-stage development and commercialization strategy.

Enliven Therapeutics plans to initiate a pivotal Phase 3 clinical trial for ELVN-001, its ATP-competitive inhibitor for chronic myeloid leukemia, in 2026. The company described ELVN-001 as having "the potential to be the best-in-class" treatment for CML patients based on data generated to date.

"I am pleased to announce the appointment of Rick Fair as Enliven's new CEO. Rick has substantial experience bringing late-stage oncology and hematology assets to commercialization. He joins us at a critical time as we plan to initiate a pivotal Phase 3 clinical trial of ELVN-001 in 2026." — Richard Heyman, Chairman of the Board, Enliven Therapeutics, Inc.

The filing includes risk factors such as the company's limited operating history, ability to advance product candidates through clinical development, and potential delays in patient enrollment for clinical trials. Enliven Therapeutics noted it faces competition from other pharmaceutical companies and must successfully demonstrate the safety and efficacy of its product candidates.